# Safety and Efficacy of Cladribine Therapy After Anti CD20 Therapy

> **NCT04640818** · — · UNKNOWN · sponsor: **Claudio Gobbi** · enrollment: 45 (estimated)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** Cladribine Oral Tablet
- **DRUG:** Rituximab
- **DRUG:** Ocrelizumab

## Key facts

- **NCT ID:** NCT04640818
- **Lead sponsor:** Claudio Gobbi
- **Sponsor class:** OTHER_GOV
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-12-17
- **Primary completion:** 2022-10-31
- **Final completion:** 2022-10-31
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2022-03-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04640818

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04640818, "Safety and Efficacy of Cladribine Therapy After Anti CD20 Therapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04640818. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*